A Phase I/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX-MC138 in Subjects with Advanced Solid Tumors

TTX-MC138 is a modular, iron oxide nanoparticle-based nanocarrier platform (TTX) coupled to an antagomir against miR-10b

• In this study, the sponsor and investigators want to learn:
  • How much of the study drug can be given with an acceptable level of side effects
  • The effects of the study drug (good and bad)
  • How much of the study drug is absorbed into the blood and how fast it is removed
  • How the study drug is acting on your body
  • If research tests can be used in the future to predict who will benefit from TTX-MC138

The study will consist of 3 study periods: Screening (up to 28 days), Treatment (28-day treatment cycles, with dosing on Day 1), and Survival Follow-Up (every 3 months). Each 28-day cycle consists of 1 dose of study drug administered as an IV infusion on Day 1 of each cycle.

Your participation in the study will last approximately 4-5 months while receiving IV infusions of TTX-MC138 once a month followed by survival follow-up every 12 weeks.